Intellia Therapeutics, Inc. (0JBU.L)
USD 12.59
(-6.07%)
USD 12.59
(-6.07%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 115.34 Million USD | -11.75% |
| 2022 | 130.7 Million USD | 76.57% |
| 2021 | 74.02 Million USD | 88.33% |
| 2020 | 39.3 Million USD | 113.9% |
| 2019 | 18.37 Million USD | 0.0% |
| 2018 | - USD | 0.0% |
| 2017 | - USD | 0.0% |
| 2016 | - USD | 0.0% |
| 2015 | - USD | 0.0% |
| 2014 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 106.29 Million USD | -4.12% |
| 2024 Q1 | 110.86 Million USD | -3.89% |
| 2023 Q3 | 118.33 Million USD | -3.27% |
| 2023 Q4 | 115.34 Million USD | -2.53% |
| 2023 FY | 115.34 Million USD | -11.75% |
| 2023 Q1 | 126.12 Million USD | -3.5% |
| 2023 Q2 | 122.33 Million USD | -3.01% |
| 2022 Q2 | 69.56 Million USD | -3.14% |
| 2022 Q1 | 71.81 Million USD | -2.98% |
| 2022 Q4 | 130.7 Million USD | 33.85% |
| 2022 FY | 130.7 Million USD | 76.57% |
| 2022 Q3 | 97.64 Million USD | 40.37% |
| 2021 Q2 | 70.67 Million USD | -2.84% |
| 2021 Q4 | 74.02 Million USD | -2.57% |
| 2021 Q1 | 72.74 Million USD | 85.07% |
| 2021 FY | 74.02 Million USD | 88.33% |
| 2021 Q3 | 75.97 Million USD | 7.5% |
| 2020 Q4 | 39.3 Million USD | 77.07% |
| 2020 FY | 39.3 Million USD | 113.9% |
| 2020 Q3 | 22.19 Million USD | -4.25% |
| 2020 Q2 | 23.18 Million USD | -4.84% |
| 2020 Q1 | 24.36 Million USD | 32.58% |
| 2019 Q1 | 19.51 Million USD | 0.0% |
| 2019 FY | 18.37 Million USD | 0.0% |
| 2019 Q4 | 18.37 Million USD | -6.47% |
| 2019 Q3 | 19.64 Million USD | -0.11% |
| 2019 Q2 | 19.66 Million USD | 0.8% |
| 2018 Q1 | - USD | 0.0% |
| 2018 FY | - USD | 0.0% |
| 2018 Q4 | - USD | 0.0% |
| 2018 Q3 | - USD | 0.0% |
| 2018 Q2 | - USD | 0.0% |
| 2017 Q4 | - USD | 0.0% |
| 2017 FY | - USD | 0.0% |
| 2017 Q1 | - USD | 0.0% |
| 2017 Q2 | - USD | 0.0% |
| 2017 Q3 | - USD | 0.0% |
| 2016 Q4 | - USD | 0.0% |
| 2016 FY | - USD | 0.0% |
| 2016 Q2 | - USD | 0.0% |
| 2016 Q3 | - USD | 0.0% |
| 2016 Q1 | - USD | 0.0% |
| 2015 Q2 | - USD | 0.0% |
| 2015 Q1 | - USD | 0.0% |
| 2015 FY | - USD | 0.0% |
| 2015 Q4 | - USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2014 FY | - USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Editas Medicine, Inc. | 36.53 Million USD | -215.705% |
| Dynavax Technologies Corporation | 256.91 Million USD | 55.103% |
| Supernus Pharmaceuticals, Inc. | 41.52 Million USD | -177.761% |
| Perrigo Company plc | 4.07 Billion USD | 97.168% |
| Illumina, Inc. | 2.26 Billion USD | 94.901% |
| Thermo Fisher Scientific Inc. | 34.91 Billion USD | 99.67% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | -11434.6% |
| Walgreens Boots Alliance, Inc. | 9.55 Billion USD | 98.793% |
| IQVIA Holdings Inc. | 14.23 Billion USD | 99.189% |
| Heron Therapeutics, Inc. | 173.75 Million USD | 33.615% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 95.733% |
| Unity Biotechnology, Inc. | 26.99 Million USD | -327.366% |
| Waters Corporation | 2.35 Billion USD | 95.103% |
| Biogen Inc. | 7.33 Billion USD | 98.428% |
| Sangamo Therapeutics, Inc. | 38.1 Million USD | -202.714% |
| Evolus, Inc. | 126.54 Million USD | 8.851% |
| Adicet Bio, Inc. | 17.7 Million USD | -551.562% |
| Cara Therapeutics, Inc. | 43.16 Million USD | -167.209% |
| bluebird bio, Inc. | 330.32 Million USD | 65.081% |
| Esperion Therapeutics, Inc. | 540.94 Million USD | 78.677% |
| FibroGen, Inc. | 170.45 Million USD | 32.331% |
| Agilent Technologies, Inc. | 2.73 Billion USD | 95.783% |
| Corbus Pharmaceuticals Holdings, Inc. | 20.88 Million USD | -452.311% |
| Homology Medicines, Inc. | 44.05 Million USD | -161.829% |
| Geron Corporation | 85.89 Million USD | -34.281% |
| Alnylam Pharmaceuticals, Inc. | 2.39 Billion USD | 95.19% |
| Amicus Therapeutics, Inc. | 445.05 Million USD | 74.083% |
| Myriad Genetics, Inc. | 145 Million USD | 20.451% |
| Viking Therapeutics, Inc. | 1.26 Million USD | -9054.444% |
| Zoetis Inc. | 6.8 Billion USD | 98.304% |
| Abeona Therapeutics Inc. | 4.4 Million USD | -2520.309% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | 94.679% |
| BioMarin Pharmaceutical Inc. | 1.13 Billion USD | 89.827% |
| Vertex Pharmaceuticals Incorporated | 808.4 Million USD | 85.732% |
| Kala Pharmaceuticals, Inc. | 36.32 Million USD | -217.556% |
| Ionis Pharmaceuticals, Inc. | 1.45 Billion USD | 92.064% |
| Atara Biotherapeutics, Inc. | 57.87 Million USD | -99.312% |
| Verastem, Inc. | 41.55 Million USD | -177.561% |
| Nektar Therapeutics | 230.4 Million USD | 49.937% |
| Axsome Therapeutics, Inc. | 186.37 Million USD | 38.11% |
| Aclaris Therapeutics, Inc. | 3.07 Million USD | -3652.31% |
| Sarepta Therapeutics, Inc. | 1.39 Billion USD | 91.742% |
| OPKO Health, Inc. | 326.56 Million USD | 64.679% |
| Exelixis, Inc. | 189.94 Million USD | 39.274% |
| Neurocrine Biosciences, Inc. | 428.4 Million USD | 73.075% |
| Corcept Therapeutics Incorporated | 151 Thousand USD | -76288.079% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| uniQure N.V. | 138.4 Million USD | 16.663% |
| Imunon, Inc. | 1.13 Million USD | -10024.349% |
| Blueprint Medicines Corporation | 774.12 Million USD | 85.1% |
| Insmed Incorporated | 1.2 Billion USD | 90.42% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | 92.306% |
| Agios Pharmaceuticals, Inc. | 56.98 Million USD | -102.404% |
| TG Therapeutics, Inc. | 110.79 Million USD | -4.108% |
| Incyte Corporation | 38.28 Million USD | -201.267% |
| Emergent BioSolutions Inc. | 877.5 Million USD | 86.855% |